The results of HLA‐incompatible kidney transplantation according to pre‐transplant crossmatch tests: Donor‐specific antibody as a prominent predictor of acute rejection

Crossmatching (XM) between organ donors and recipients is correlated with clinical outcomes. This study evaluates the results of HLA‐incompatible kidney transplant (HLA‐i KT) according to pre‐transplant XM modalities.

[1]  E. Benedetti,et al.  Living Donor Kidney Transplantation Across Positive Crossmatch: The University of Illinois at Chicago Experience , 2009, Transplantation.

[2]  M. Stegall,et al.  A Comparison of Plasmapheresis Versus High‐Dose IVIG Desensitization in Renal Allograft Recipients with High Levels of Donor Specific Alloantibody , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  Y. Kodera,et al.  Negative regulation of HLA-DR expression on endothelial cells by anti-blood group A/B antibody ligation and mTOR inhibition. , 2017, Transplant immunology.

[4]  L. Kucirka,et al.  Desensitization in HLA-incompatible kidney recipients and survival. , 2011, The New England journal of medicine.

[5]  M. Stegall,et al.  Alloantibody Levels and Acute Humoral Rejection Early After Positive Crossmatch Kidney Transplantation , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  J. Watanabe,et al.  IVIG and HLA Antibodies. Evidence for Inhibition of Complement Activation but Not for Anti‐Idiotypic Activity , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  S. Jacobs,et al.  Positive Cross‐Match Living Donor Kidney Transplantation: Longer‐Term Outcomes , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  S. Jordan,et al.  Six‐year outcomes in broadly HLA‐sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab , 2016, Transplant international : official journal of the European Society for Organ Transplantation.

[9]  S. Jordan,et al.  Rituximab and intravenous immune globulin for desensitization during renal transplantation. , 2008, The New England journal of medicine.

[10]  E. Reed,et al.  Preformed cytotoxic antibodies in potential allograft recipients: recent data. , 2005, Human immunology.

[11]  M. Mihatsch,et al.  Risk stratification by the virtual crossmatch: a prospective study in 233 renal transplantations , 2011, Transplant international : official journal of the European Society for Organ Transplantation.

[12]  J. Jung,et al.  Analysis of 4000 kidney transplantations in a single center , 2016, Medicine.

[13]  J. Azzi,et al.  Long-Term Outcomes of Kidney Transplantation Across a Positive Complement-Dependent Cytotoxicity Crossmatch , 2014, Transplantation.

[14]  T. Larson,et al.  Overcoming a Positive Crossmatch in Living‐Donor Kidney Transplantation , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  M. Stegall,et al.  Survival Benefit with Kidney Transplants from HLA-Incompatible Live Donors. , 2016, The New England journal of medicine.

[16]  M. Salifu,et al.  Poor kidney allograft survival associated with positive B cell - Only flow cytometry cross matches: a ten year single center study. , 2013, Human immunology.

[17]  C. Magee,et al.  Renal Transplantation in Patients With Positive Lymphocytotoxicity Crossmatches: One Center’s Experience , 2008, Transplantation.

[18]  F. Christiansen,et al.  Transnational validation of the Australian algorithm for virtual crossmatch allocation in kidney paired donation. , 2013, Human immunology.

[19]  S. Jordan,et al.  Use of Intravenous Immune Globulin and Rituximab for Desensitization of Highly HLA-Sensitized Patients Awaiting Kidney Transplantation , 2010, Transplantation.

[20]  K. Budde,et al.  Dynamics and epitope specificity of anti-human leukocyte antibodies following renal allograft nephrectomy. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  M. Stegall,et al.  Five‐Year Outcomes in Living Donor Kidney Transplants With a Positive Crossmatch , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  J. Alberú,et al.  Impact of pretransplant exposure to allosensitization factors generating HLA antibodies in the Luminex era. , 2016, Transplant immunology.

[23]  N. Greenspan,et al.  Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. , 1999, Journal of immunology.

[24]  B. Banas,et al.  Analysis of Luminex-based Algorithms to Define Unacceptable HLA Antibodies in CDC-crossmatch Negative Kidney Transplant Recipients , 2018, Transplantation.

[25]  D. Stablein,et al.  Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. , 2004, Journal of the American Society of Nephrology : JASN.

[26]  Walter K. Kremers,et al.  Baseline Donor‐Specific Antibody Levels and Outcomes in Positive Crossmatch Kidney Transplantation , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[27]  J. Friedewald,et al.  Assessing Antibody Strength: Comparison of MFI, C1q, and Titer Information , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[28]  A. Webster,et al.  Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in Transplantation , 2013, Transplantation.

[29]  J. Cooper,et al.  Clinical Significance of Pretransplant Donor‐Specific Antibodies in the Setting of Negative Cell‐Based Flow Cytometry Crossmatching in Kidney Transplant Recipients , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[30]  V. Sharma,et al.  Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure , 2015, Transplantation.

[31]  D. Rush,et al.  Banff 2013 Meeting Report: Inclusion of C4d‐Negative Antibody‐Mediated Rejection and Antibody‐Associated Arterial Lesions , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[32]  J. Ravetch,et al.  Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. , 2001, Science.

[33]  J. Platt,et al.  IgM in the Kidney: A Multiple Personality Disorder , 2015, Kidney international.

[34]  J. Jung,et al.  Impact of pretransplant donor‐specific antibodies on kidney allograft recipients with negative flow cytometry cross‐matches , 2018, Clinical transplantation.

[35]  B. Banas,et al.  Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.